ViGeneron Signs Target-Specific Collaboration and Option Agreement with Regeneron to Develop & Commercialize AAV Based Gene Therapies for Inherited Retinal Disease
Shots:
- ViGeneron to receive up front along with research funding & is also eligible to receive an option exercise fee, development & commercial milestone along with royalties on net sales. Both companies will generate & validate vgAAV-based therapeutic products for 1 undisclosed IRD target
- Regeneron gets an exclusive license option to develop, commercialize & manufacture the vgAAV-based product for the specific target & also gets access to ViGeneron’s vgAAV capsids for one IRD target
- The collaboration will validate ViGeneron’s vgAAV platform & ophthalmic gene therapy expertise to develop the AAV based gene therapies for inherited eye disease patients
Ref: Globe Newswire | Image: Regeneron
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
